Clinical Rheumatology

, Volume 33, Issue 5, pp 719–723 | Cite as

Demyelinizing neurological disease after treatment with tumor necrosis factor alpha-inhibiting agents in a rheumatological outpatient clinic: description of six cases

  • Ali Theibich
  • Lene Dreyer
  • Melinda Magyari
  • Henning Locht
Case Based Review

Abstract

Biological treatment with inhibitors of the pro-inflammatory cytokine TNF-alpha has dramatically improved the disease course of several chronic rheumatologic conditions. Adverse events (AEs) are primarily infections and hypersensitivity reactions. Demyelinizing neurological symptoms resembling multiple sclerosis (MS) have been described as a rare AE. During about 10-year use of anti TNF-alpha, the Danish Medicines Agency has recorded eight cases of MS like AEs. The objective of this study was to estimate the incidence of demyelinizing AEs both in the central and peripheral nervous system after treatment with anti TNF-alpha in a cohort of patients from a large rheumatologic outpatient clinic in Copenhagen. In a 4-year period from January 2008 to December 2011, approximately 550 patients annually were undergoing treatment with anti TNF-alpha inhibitors in our department. We collected data on all patients who developed neurological symptoms during this time period. We found six patients with signs of demyelinizing neurological disorders: four resembling MS, one MS-like condition, and one multifocal motor neuropathy. During a relatively short time period, we found a remarkably high number of neurological demyelinizing AEs probably linked to anti TNF-alpha treatment. The AEs were not associated with a single anti TNF-alpha agent and were thus presumably a class effect. The data presented suggest that neurological AEs may be underreported. We advocate that physicians handling patients during treatment with TNF inhibitors are aware of this potentially serious AE and report these events to the proper medical authorities.

Keywords

Anti TNF-alpha inhibitors Arthritis Multiple sclerosis 

References

  1. 1.
    Sharief MK, Hentges R (1991) Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 325:467–472PubMedCrossRefGoogle Scholar
  2. 2.
    The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group (1999) TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology 53:457–465CrossRefGoogle Scholar
  3. 3.
    Liu J, Marino MW, Wong G et al (1998) TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat Med 4:78–83PubMedCrossRefGoogle Scholar
  4. 4.
    Tanno M, Nakamura I, Kobayshi S et al (2006) New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. Clin Rheumatol 25(6):929–933PubMedCrossRefGoogle Scholar
  5. 5.
    Lozeron P, Denier C et al (2009) Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. Arch Neurol 66(4):490–497PubMedCrossRefGoogle Scholar
  6. 6.
    Li SY, Birnbaum AD, Goldstein DA (2010) Optic neuritis associated with adalimumab in the treatment of uveitis. Ocul Immunol Inflamm 18(6):475–481PubMedCrossRefGoogle Scholar
  7. 7.
    Ascherio A, Munger K (2008) Epidemiology of multiple sclerosis: from risk factors to prevention. Semin Neurol 28:17–28PubMedCrossRefGoogle Scholar
  8. 8.
    Tristano AG (2010) Neurological adverse events associated with anti-tumor necrosis factor α treatment. J Neurol 257:1421–1431PubMedCrossRefGoogle Scholar
  9. 9.
    Fernández-Espartero MC, Pérez-Zafrilla B, Naranjo A et al (2011) Demyelinating disease in patients treated with TNF antagonists in rheumatology: data from BIOBADASER, a pharmacovigilance database, and a systematic review. Semin Arthritis Rheum 40:330–337PubMedCrossRefGoogle Scholar
  10. 10.
    Winthrop KL, Chen L, Fraunfelder FW et al (2013) Initiation of anti-TNF therapy and the risk of optic neuritis: from the safety assessment of biological thERapy (SABER) study. Am J Ophthalmol 155:183–189PubMedCrossRefGoogle Scholar
  11. 11.
    Gregory AP, Dendrou CA, Attfield KE et al (2012) TNF receptor 1 genetic risk mirrors outcome of anti-TNF therapy in multiple sclerosis. Nature 488(7412):508–511. doi:10.1038/nature11307 PubMedCrossRefGoogle Scholar

Copyright information

© Clinical Rheumatology 2013

Authors and Affiliations

  • Ali Theibich
    • 1
  • Lene Dreyer
    • 1
  • Melinda Magyari
    • 2
  • Henning Locht
    • 3
  1. 1.Department of RheumatologyGentofte HospitalHellerupDenmark
  2. 2.Danish Multiple Sclerosis Research Centre, Department of Neurology, and the Danish Multiple Sclerosis Registry, Neuroscience Centre, RigshospitaletUniversity of CopenhagenCopenhagenDenmark
  3. 3.Department of RheumatologyFrederiksberg HospitalFrederiksbergDenmark

Personalised recommendations